Bioxytran (BIXT) Research & Development (2021 - 2026)
Bioxytran (BIXT) recorded Research & Development of $255,479 in Q2 2026, up 149.2% from $102,500 a year earlier and up 13.3% from the prior quarter.
Powered by 
Analysis
Bioxytran (BIXT) Research & Development (2021 - 2026) Analysis & Trends
On a TTM basis, Bioxytran's Research & Development came in at $482,958 as of Jun 30, 2026, down 10.1% year-over-year; for FY2025, it was $454,000, up 304.1% from FY2024.
- Annual Research & Development has a five-year compound annual growth rate of -3.6% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $112,337 in FY2024 (-90.2%), $1.15 million in FY2023 (-10.1%), $1.28 million in FY2022 (-36.5%) and $2.01 million in FY2021 (+269.8%).
- The Q2 2026 figure is the highest quarterly Research & Development since Q1 2025.
- On a year-over-year basis, Research & Development rose in 1 of the last five quarters, with an average decline of 31.6%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 246.9% in Q2 2023, against a decline of 94.2% in Q4 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Bioxytran | 2.29 Mn | 1.13 Mn | - | 255,479.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 255,479.00 |
| Mar 31, 2026 | 225,479.00 |
| Dec 31, 2025 | 2,000.00 |
| Jun 30, 2025 | 102,500.00 |
| Mar 31, 2025 | 349,500.00 |
| Dec 31, 2024 | 34,337.00 |
| Sep 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 544,438.00 |
| Sep 30, 2023 | 316,129.00 |
| Jun 30, 2023 | 149,638.00 |
| Mar 31, 2023 | 139,004.00 |
| Dec 31, 2022 | 518,630.00 |
| Sep 30, 2022 | 475,872.00 |
| Jun 30, 2022 | 43,141.00 |
| Mar 31, 2022 | 240,125.00 |
| Dec 31, 2021 | 766,115.00 |
| Sep 30, 2021 | 181,962.00 |
| Jun 30, 2021 | 718,652.00 |
| Mar 31, 2021 | 347,033.00 |
API Access
Bioxytran Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=BIXT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "BIXT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=BIXT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();